Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Brain Pathology

• Publication date

  2008-01-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1750-3639.2007.00117.xPMID 18241240PMCID PMC2689097
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Alzheimer Disease With Amygdala Lewy Bodies: A Distinct Form of &agr;-Synucleinopathy

  2006cited by this paper
• Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype.

  2006influential reference
• Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered

  2006cited by this paper
• Diagnosis and management of dementia with Lewy bodies

  2005cited by this paper
• Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium

  2005cited by this paper
• Pathological entity of dementia with Lewy bodies and its differentiation from Alzheimer’s disease

  2004cited by this paper
• Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies

  2004cited by this paper
• Neuropathological stageing of Alzheimer-related changes

  2004influential reference
• Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease.

  2003cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies

  2003cited by this paper
• Progression and staging of Lewy pathology in brains from patients with dementia with Lewy bodies.

  2002cited by this paper
• Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases

  2002cited by this paper
• Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages)

  2002influential reference
• Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry

  2000cited by this paper
• Epitope mapping of LB509, a monoclonal antibody directed against human α-synuclein

  1999cited by this paper
• Report of the second dementia with Lewy body international workshop

  1999cited by this paper
• Epitope mapping of LB509, a monoclonal antibody directed against human alpha-synuclein.

  1999cited by this paper
• Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes.

  1998cited by this paper
• Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB)

  1996cited by this paper
• Geographically Overlapping Alzheimer's Disease Registries: Comparisons and Implications

  1995cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1993cited by this paper
• The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)

  1991cited by this paper
• University of Washington Alzheimer’s Disease Patient Registry (ADPR): 1987–8

  1990cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• Statistical Methods for Rates and Proportions, 2nd ed

  1981cited by this paper
• Statistical methods for rates and proportions

  1973cited by this paper

• Alpha-Synuclein in Neurodegeneration: From Shared Biology to Disease-Specific Phenotypes

  2026cites this paper
• Microglial reactivity in the hippocampal CA2 is associated with advanced neuronal α-synucleinopathy

  2026cites this paper
• Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer’s disease

  2025cites this paper
• Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers

  2025cites this paper
• Pathological Characterisation of Posterior Cortical Atrophy in Comparison With Amnestic Alzheimer's Disease

  2025cites this paper
• Alpha-synuclein regulates nucleolar DNA double-strand break repair in melanoma

  2025cites this paper
• Biological effects of pathologies in Lewy body diseases: why timing matters.

  2025cites this paper
• Reliability and modeling of digital histological measurements in Alzheimer’s disease neuropathologic change and Lewy body disease

  2025cites this paper
• A novel hierarchical framework elucidating regional differences in α-synuclein and tau co-pathology in military veterans with parkinsonism.

  2025cites this paper
• Amygdala-predominant Lewy bodies associate with cognitive decline and amygdala atrophy in Alzheimer’s disease neuropathological change

  2025cites this paper
• Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies

  2025cites this paper
• Neuropsychiatric symptom phenotypes for early detection of risk in older adults

  2025cites this paper
• Where do PDD and DLB SYNdromes fit in neuronal alpha-SYNuclein biological frameworks?

  2025cites this paper
• Neuropathological comorbidity, genetics and cognition in a Chinese community-based autopsy cohort

  2025cites this paper
• Amygdala-predominant α-synuclein pathology is associated with exacerbated hippocampal neuron loss in Alzheimer’s disease

  2024cites this paper
• Current insights and assumptions on α-synuclein in Lewy body disease

  2024cites this paper
• Clinical and diagnostic implications of Alzheimer's disease copathology in Lewy body disease.

  2024cites this paper
• Amygdala-predominant α-synuclein pathology exacerbates hippocampal neuron loss in Alzheimer’s disease

  2024cites this paper
• In vivo detection of Alzheimer's and Lewy body disease concurrence: Clinical implications and future perspectives

  2024cites this paper
• Clinicopathological correlation of cerebrospinal fluid alpha‐synuclein seed amplification assay in a behavioral neurology autopsy cohort

  2024cites this paper
• Multiple biomarkers improve diagnostic accuracy across Lewy body and Alzheimer's disease spectra

  2024cites this paper
• Pathology vs pathogenesis: Rationale and pitfalls in the clinicopathology model of neurodegeneration.

  2023cites this paper
• α-Synuclein conformers reveal link to clinical heterogeneity of α-synucleinopathies

  2023cites this paper
• A Preliminary Comparison of the Methylome and Transcriptome from the Prefrontal Cortex Across Alzheimer’s Disease and Lewy Body Dementia

  2023cites this paper
• α-Synuclein pathology in post-mortem retina and optic nerve is specific for α-synucleinopathies

  2023cites this paper
• Perception of Fragmented Letters by Patients With Pathologically Confirmed Dementia With Lewy Bodies or Alzheimer Disease

  2022cites this paper
• Regional distribution and maturation of tau pathology among phenotypic variants of Alzheimer’s disease

  2022cites this paper
• One Autopsy Proved Neocortical Lewy Body Disease Without the Involvement of the Olfactory Bulb and Brainstem

  2022cites this paper
• α‐Synuclein Seed Amplification in CSF and Brain from Patients with Different Brain Distributions of Pathological α‐Synuclein in the Context of Co‐Pathology and Non‐LBD Diagnoses

  2022cites this paper
• Shrinkage of olfactory amygdala connotes cognitive impairment in patients with Parkinson’s disease

  2022cites this paper
• CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology

  2022cites this paper
• Nuclear alpha-synuclein is present in the human brain and is modified in dementia with Lewy bodies

  2022cites this paper
• Neurodegeneration: 2022 update.

  2022cites this paper
• Plasma biomarkers for Alzheimer’s Disease in relation to neuropathology and cognitive change

  2022cites this paper
• Proteome-wide discovery of cortical proteins that may provide motor resilience to offset the negative effects of pathologies in older adults.

  2022cites this paper
• Impact of APOE ε4 genotype on initial cognitive symptoms differs for Alzheimer’s and Lewy body neuropathology

  2021cites this paper
• Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study

  2021cites this paper
• Neuropathology of Alzheimer’s Disease

  2021cites this paper
• Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment

  2021cites this paper
• Dementia with Lewy bodies - a clinicopathological update.

  2020cites this paper
• Origins of atrophy in Parkinson linked to early onset and local transcription patterns

  2020cites this paper
• The interaction of α-synuclein and Tau: A molecular conspiracy in neurodegeneration?

  2020cites this paper
• Trans-synaptic and retrograde axonal spread of Lewy pathology following pre-formed fibril injection in an in vivo A53T alpha-synuclein mouse model of synucleinopathy

  2020cites this paper
• The development and convergence of co-pathologies in Alzheimer's disease.

  2020cites this paper
• Pathological Influences on Clinical Heterogeneity in Lewy Body Diseases

  2020cites this paper
• Synucleinopathies: Where we are and where we need to go

  2020cites this paper
• Association Between Sepsis and Microvascular Brain Injury.

  2019cites this paper
• Unified Staging System for Lewy Body Disorders: Clinicopathologic Correlations and Comparison to Braak Staging.

  2019cites this paper
• Seeding and structural varibility in α-synucleinopathies

  2019cites this paper
• Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update—I. Hypokinetic-rigid movement disorders

  2019cites this paper
• The center of olfactory bulb‐seeded α‐synucleinopathy is the limbic system and the ensuing pathology is higher in male than in female mice

  2019cites this paper
• Amygdala sign, a FDG-PET signature of dementia with Lewy Bodies.

  2019cites this paper
• Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but 'failure to fit' is highly dependent on staging system applied.

  2019cites this paper
• Unveiling the olfactory proteostatic disarrangement in Parkinson's disease by proteome-wide profiling.

  2019cites this paper
• Dementia with Lewy bodies: an update and outlook

  2019cites this paper
• The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases

  2018cites this paper
• APOE DNA methylation is altered in Lewy body dementia

  2018cites this paper
• Is Braak staging valid for all types of Parkinson’s disease?

  2018cites this paper
• Risk factors of hippocampal sclerosis in the oldest old

  2018cites this paper
• The Contribution of Tau, Amyloid-Beta and Alpha-Synuclein Pathology to Dementia in Lewy Body Disorders

  2018cites this paper
• Minimal neuropathologic diagnosis for brain banking in the normal middle-aged and aged brain and in neurodegenerative disorders.

  2018cites this paper
• Novel conformation‐selective alpha‐synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease

  2017cites this paper
• Alpha-synucleinopathies.

  2017cites this paper
• Amygdala α-Synuclein Pathology in the Population-Based Vantaa 85+ Study

  2017influential citation
• Glucose levels during life and neuropathologic findings at autopsy among people never treated for diabetes.

  2016cites this paper
• Pathological α-synuclein distribution in subjects with coincident Alzheimer’s and Lewy body pathology

  2016cites this paper
• Non-Amyloid-β Component of Human α-Synuclein Oligomers Induces Formation of New Aβ Oligomers: Insight into the Mechanisms That Link Parkinson's and Alzheimer's Diseases.

  2016cites this paper
• Staging/typing of Lewy body related alpha-synuclein pathology

  2016cites this paper
• Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion‐like behaviour of alpha‐synuclein

  2016cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1182 Altered proteins in the aging brain

  2016cites this paper
• Distribution and Load of Amyloid-&bgr; Pathology in Parkinson Disease and Dementia with Lewy Bodies

  2016cites this paper
• A Peruvian family with a novel PARK2 mutation: Clinical and pathological characteristics.

  2015cites this paper
• Neuropathologically mixed Alzheimer’s and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes

  2015cites this paper
• Multiple pathologies are common and related to dementia in the oldest-old

  2015cites this paper
• Progressive aggregation of alpha-synuclein and selective degeneration of Lewy inclusion-bearing neurons in a mouse model of parkinsonism

  2015cites this paper
• Intracellular processing of disease-associated α-synuclein in the human brain suggests prion-like cell-to-cell spread.

  2014cites this paper
• Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?☆

  2014cites this paper
• Neuropathology of Dementia Disorders

  2014cites this paper
• Alpha-synuclein and tau: teammates in neurodegeneration?

  2014cites this paper
• The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis

  2014cites this paper
• Staged pathology in Parkinson's disease.

  2014cites this paper
• Neuropathology of Parkinson’s Disease

  2014cites this paper
• Challenges in the Neuropathological Diagnosis of Dementias

  2013cites this paper
• Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies

  2013cites this paper
• The current consensus criteria for the neuropathologic diagnosis of Alzheimer ’ s disease ( AD ) , known as the National Institute on Aging / Reagan Institute of the Alzheimer Association Consensus Recommendations for the Postmortem Diagnosis of AD or

  2013cites this paper
• Neuropathological correlates of cerebral multimorbidity.

  2013cites this paper
• APOE ε4 increases risk for dementia in pure synucleinopathies.

  2013influential citation
• Differential microglial activation in neurodegenerative diseases

  2013cites this paper
• Limelight on Alpha-Synuclein: Pathological and Mechanistic Implications in Neurodegeneration

  2013cites this paper
• The function of α-synuclein.

  2013cites this paper
• The Lewy Body in Parkinson’s Disease and Related Neurodegenerative Disorders

  2012cites this paper
• GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology

  2012cites this paper
• Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts

  2012cites this paper
• The role of α-synuclein in neurodegeneration — An update

  2012cites this paper
• Featured Articles National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

  2012cites this paper
• Recent progress and concerns in dementia: Distinguishing Alzheimer's disease and dementia with Lewy bodies via biochemical markers in the cerebrospinal fluid

  2012cites this paper
• Staging of Lewy-related pathology in dementia.

  2012cites this paper
• National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

  2012cites this paper
• Novel Antibody Capture Assay for Paraffin‐Embedded Tissue Detects Wide‐Ranging Amyloid Beta and Paired Helical Filament–Tau Accumulation in Cognitively Normal Older Adults

  2012cites this paper
• Neuropathology underlying clinical variability in patients with synucleinopathies

  2011cites this paper